TX-FLUENCE
10.6.2022 12:32:12 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its full speaker schedule, including CEO David Cohen and General Manager of EMEA Timo Bongartz, at the 2022 GreenTech Amsterdam conference, the leading global meeting place for the horticulture industry.
Fluence speakers will discuss new innovations in data-driven horticulture strategies, the latest research on the effects of next-generation lighting solutions for plant growth and the role of LED lighting in the cannabis industry. Fluence horticulture specialists will also be available to discuss the company’s comprehensive product suite at booth No. 05.524. This includes display of Fluence’s newest luminaires and lighting controls: RAPTR —the company’s one-to-one HPS replacement fixture—Wireless Flex Dimming , SPYDR Fang , VYNE and RAZR Modular System .
“GreenTech Amsterdam is one of the world’s premier agricultural conferences. The team at Fluence is excited to stand alongside some of the most notable experts in the industry in a series of informative panels for growers,” Cohen said. “I always value the opportunity to speak face-to-face with our customers and gain valuable insight into what solutions growers are looking for. We’re confident that Fluence’s expanded product suite will support and exceed grower’s expectations for crop performance.”
Fluence’s speaking sessions will include:
- Medicinal cannabis in the spotlight (June 14, 11:00-11:45 a.m. CET) , featuring Casey Rivero, cannabis solutions architect for Fluence
- Data-driven horticulture: Collecting and interpreting data, how much is enough? (June 14, 3:30-4:15 p.m. CET) , moderated by Theo Tekstra, technical director of EMEA for Fluence
- Leading the Cannabis Industry into the Next Decade (June 15, 2:15-3:00 p.m. CET) , moderated by Fluence CEO David Cohen and featuring Elad Toby, founder of Remy, Levin Amweg, co-founder and CEO of Cannerald, and Timo Bongartz, Fluence’s general manager of EMEA
- Save energy by applying new innovations and solutions (June 16, 11:45 a.m. - 12:30 p.m. CET) , featuring Theo Tekstra, technical director of EMEA for Fluence
- Is Indoor Growing Sustainable? (June 16, 1:15-2:00 p.m. CET) , featuring Timo Bongartz, general manager of EMEA for Fluence
“Our priority is to create and deploy the most advanced lighting solutions for the entire EMEA region and beyond,” Bongartz said. “GreenTech is a critical opportunity to illuminate growers on what’s possible when they convert to Fluence’s LED lighting solutions. Growers, partners and colleagues: We can’t wait to see you!”
For more information on Fluence, its products and the future of LED lighting, visit the team at booth No. 05.524, or visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom